High Dosage Esomeprazole and Baclofen for Therapy of Gastroesophageal Reflux Disease
NCT ID: NCT00461604
Last Updated: 2008-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2006-10-31
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aim of the study was to evaluate the influence of high dosage PPI-therapy and additional baclofen in patients with persistent symptoms and objectified gastroesophageal reflux.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Symptom Adapted Therapy in GERD Patients
NCT00343161
Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux
NCT00414856
Important Correlation Between Anxiety and Reflux Symptoms in Patients With Gastroesophageal Reflux Disease
NCT06151067
The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or Esomeprazole
NCT04720781
A Placebo Controlled Trial With Baclofen for the Treatment of GERD Patients With Incomplete PPI Response
NCT03835442
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* informed consent
* patients with persistent reflux-associated symptoms despite PPI-therapy
Exclusion Criteria
* synthetic liver diseases
* renal failure
* disability to understand informed consent
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Technical University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Technische Universität München
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexander Meining, MD
Role: PRINCIPAL_INVESTIGATOR
Technische University Munich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Technical University of Munich
Munich, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1690/07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.